Trump’s administration reclassifies medical marijuana to Schedule III, easing federal barriers to research while leaving non-approved products exposed to prosecution.
The Trump administration has taken marijuana out of the federal government’s most dangerous drug category and moved state-licensed medical marijuana to Schedule III, a shift officials say should make research easier and recognize medical use without legalizing recreational cannabis at the federal level. The order, signed by the acting attorney general, marks a major change in how Washington treats a drug that remains heavily regulated, still contested, and, by experts’ account, not fully decriminalized.
A federal reclassification with narrow but significant reach
The move from Schedule I to Schedule III is the core of the story: it lowers the federal risk level assigned to state-licensed medical marijuana and opens the door to more scientific research and potential tax benefits, according to reports on the order. But the policy stops well short of nationwide legalization, and it does not erase federal criminal exposure for products that are not FDA-approved, as experts noted in coverage of the change.
That balance — easier access for research, but not full legalization — sits at the heart of the administration’s rationale. The White House’s earlier signals, including the December 2025 order discussed by The Guardian and El País, framed the issue as a medical-policy adjustment rather than a broader cultural reversal.
What changes under Schedule III
By moving medical marijuana out of the category reserved for the most dangerous drugs, the administration is changing how the federal government regards a substance already licensed in most states. The practical effect, as described in AP’s explanation of the federal order, is a loosening of federal restrictions that could make it easier to study medical cannabis and alter the tax treatment of related activity.
| Policy area | Schedule I position | Schedule III position | Source |
|---|---|---|---|
| Federal risk category | Most dangerous drugs | Less dangerous drug | AP’s report on the reclassification |
| Research access | Tighter barriers | Easier research | The Guardian’s coverage of the shift |
| Tax treatment | More restrictive | Tax benefits may open | AP’s report on the reclassification |
| Legal status of recreational use | Not legalized | Still not legalized federally | El País on the Trump order |
The federal government is therefore not making a sweeping moral or criminal-law judgment about cannabis as a whole. It is carving out a narrower medical lane, one that keeps the substance under control but acknowledges that the old federal classification no longer matches the administration’s own policy direction.
The move would ease some restrictions and expand research while stopping short of nationwide legalization.
AP coverage of the Trump administration’s policy shift
What the order does not do
Despite the headline-grabbing shift, the order leaves important limits in place. Experts quoted in coverage said users can still face prosecution for cannabis products that are not FDA-approved, meaning the reclassification should not be mistaken for blanket immunity. That distinction matters because federal drug policy remains a patchwork of categories, approvals and enforcement risks.
- It does not legalize recreational cannabis at the federal level.
- It does not remove the possibility of prosecution for non-approved cannabis products.
- It applies to state-licensed medical marijuana, not a broad federal endorsement of all cannabis markets.
- It signals a narrower medical-policy shift rather than full federal legalization.
This limited scope helps explain why the administration could describe the move as a reform while still preserving core federal enforcement tools. In other words, the government has changed the label and the regulatory frame, but not rewritten the whole rulebook.
Research, medicine and the politics of proof
One of the most concrete consequences of the order is the promise of easier research. The administration’s step is being presented as a way to support medical study, and that has obvious implications for a field where federal classification has long constrained investigation. The policy logic is straightforward: if the drug is treated as less dangerous, the paperwork and institutional barriers around research should become easier to manage.
That rationale also fits the broader medical framing used by the administration. The order was repeatedly described in the supplied reports as a measure to foster medical use, not to open a recreational market. That distinction is central to understanding the politics of the move: it is both a loosening and a containment strategy.
The broader policy climate remains unsettled
The federal shift lands in a wider environment where cannabis policy remains volatile on both sides of the Atlantic. In Europe, the EU drugs agency has warned that the market is becoming more complex, with stronger cannabis and other higher-risk substances creating new public-health concerns, according to its 2026 report and related coverage from Euronews and the EUDA’s report materials. That European backdrop is not the same debate, but it shows how cannabis policy is still being pulled between medical, enforcement and public-health priorities.
The administration’s move also arrives amid a noisy international policy conversation. Reports from Cannabis Europa say Europe still lacks an EU-level legalization model, while AP’s other report on the federal order underscored that the U.S. change is an easing step, not a finished settlement. The message on both continents is similar: regulation is moving, but consensus is not.
| Source | What it says | Relevance to the U.S. order |
|---|---|---|
| AP | Rescheduling opens research and tax benefits | Shows the practical policy effects |
| The Guardian | Step would ease restrictions and expand research | Frames the shift as limited reform |
| El País | Medical use is the explicit goal, not recreational legalization | Clarifies the administration’s intent |
| AP | Federal regulation of state-licensed medical marijuana changes | Explains the administrative effect |
What readers should watch next
The next stage will be less about symbolism than administration: how federal agencies interpret the reclassification, how researchers use the easier pathway, and whether the tax and compliance effects described in reporting begin to materialize. Because the order does not legalize cannabis nationwide, the practical stakes remain concentrated in medical access, research design and the continued boundary between approved and non-approved products.
For now, the significance is clear enough. The federal government has moved state-licensed medical marijuana out of its harshest category and into a less punitive frame, but it has done so with explicit limits. That makes the policy a reform, not a resolution.
Trump’s rescheduling order is best understood as a targeted federal correction rather than a sweeping legalization wave. It lowers the category assigned to state-licensed medical marijuana, opens the way for more research and possible tax relief, and still leaves major legal and enforcement limits intact. In a policy area defined by incremental change, that is a substantial move — just not the final one.
Sources
- Trump’s cannabis order will still leave users at risk of prosecution, experts say (theguardian.com)
- Trump firma un decreto para sacar la marihuana del grupo de las drogas más peligrosas y permitir su uso con fines médicos (elpais.com)
- Trump reclassifies state-licensed medical marijuana as a less-dangerous drug in a historic shift (apnews.com)
- Trump administration moves to ease federal restrictions on marijuana (theguardian.com)
- New health risks emerge as Europe’s drug market grows more complex, EU agency warns (euronews.com)
- News release (euda.europa.eu)
- European Cannabis Regulations by Country:The 2026 Business Guide (cannabis-europa.com)
- What to know about a federal order reclassifying medical marijuana as a less dangerous drug (apnews.com)